CRIZOCENT 250 MG
Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including
CRIZONIX 250 MG
Crizonix Capsule 250 mg Indications Crizotinib is a kinase inhibitor indicated for the treatment of patients with- Metastatic non-small cell lung
ELBONIX 50 MG
COMPOSITION Elbonix 50 tablet : Each film coated tablet contains EltrombopagOlamine INN equivalent to Eltrombopag 50 mg. Therapeutic class: Hematopoietic Agent PHARMACOLOGICAL
IBRUXEN 140 MG
Ibruxen Capsule Ibrutinib 140 mg Everest Pharmaceuticals Ltd. Indications Mantle Cell Lymphoma: Ibrutinib is indicated for the treatment of patients with
LAPANIX 250 MG
LAPANIX 250 MG Lapatinib Beacon Pharmaceuticals Ltd. Product Description: Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase
LARONIB 25 MG
DESCRIPTION Laronib Larotrectinib 25 mg & 100 mg COMPOSITION LARONIB 25 capsules: Each capsule contains Larotrectinib Sulfate INN equivalent to
LENVANIX 10 MG
Lenvanix (lenvatinib) 10 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor
LUCISUN 50
Brand name: LUCISUN 50 Pack: Pack of 28 capsules Key ingredient: Sunitinib Description LUCISUN 50 provides targeted therapy against various cancers.
LYNIB 100 MG
Lynib medicine 100mg Olaparib treats Ovarian cancer Brand name: Lynib Active ingredient: Olparib Content: 100mg Form: Capsules Package: 1 box of
MEZOXIA 160 MG
Mezoxia Tablet Megestrol Acetate 160 mg Everest Pharmaceuticals Ltd. Indications Megestrol Acetate is indicated for the palliative treatment of advanced carcinoma